搜索
Assertio Holdings Inc
ASRT添加自选
23.495USD
0.0000.00%
收盘 07/02, 13:00（美东）报价延迟15分钟
151.86M总市值
亏损市盈率 TTM
关键数据
--今开
0.000最高
0.00成交量
亏损市盈率 TTM
377.21市盈率动
--股息TTM
4.26%换手率
23.500昨收
0.000最低
0.00成交额
亏损市盈率静
1.61市净率
0.00%股息率 TTM
-14.34%ROA
23.46052周最高
0.58量比
-21.58M净利润
6.42M总股本
-5.5516每股收益TTM
0.50Beta
-38.76%ROE
8.61052周最低
0.09%振幅
14.28%毛利率
151.86M总市值
0.22回报/风险
3.17%风险率
TradingKey Assertio Holdings Inc股票评分
单位: USD 更新时间: 2026-06-15操作建议
Assertio Holdings Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在药品行业排名96/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价24.43。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Assertio Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Assertio Holdings Inc亮点
亮点风险
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
分析师目标
根据
0
位分析师
--
评级
24.433
目标均价
+3.97%
涨幅空间
Assertio Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Assertio Holdings Inc简介
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
公司代码ASRT
公司Assertio Holdings Inc
CEOReisenauer (Mark L)
网址https://www.assertiotx.com/
相关品种
热门品种
常见问题
Assertio Holdings Inc(ASRT)的当前股价是多少？
Assertio Holdings Inc(ASRT)的当前股价是 23.50。
Assertio Holdings Inc的股票代码是什么？
Assertio Holdings Inc的股票代码是ASRT。
Assertio Holdings Inc股票的52周最高点是多少？
Assertio Holdings Inc股票的52周最高点是23.46。
Assertio Holdings Inc股票的52周最低点是多少？
Assertio Holdings Inc股票的52周最低点是8.61。
Assertio Holdings Inc的市值是多少？
Assertio Holdings Inc的市值是151.86M。
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是多少
Assertio Holdings Inc(ASRT)股票的每股收益（EPS TTM）是-4.74。